Key Takeaway: Cognition Therapeutics has announced a proof-of-concept clinical trial for CT1812, which aims to slow cognitive decline. The trial's results are expected to provide insights into the drug's efficacy. Further details on the trial's design and outcomes have not been disclosed.
Price reaction · baseline $0.7585 (2024-08-22 close) · hit pre-market · 2 other CGTX headline(s) in the window, move may be shared
day 0 close · peak
-2.7%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.